<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 302 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page301.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=302">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 302 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 302</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=302"><img src="../thumb/302.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Anti-Microbials - 18.12                                                        2020-04 / 265
       (S4) TABS. 42/20.2.8/0941, 0942.  Indications: Part of anti-retroviral combinat.ther. for treatm.of   dine is antagonist., probenecid incr.zidovudine mean half-life & area
       710268-002: 150 mg, 60, R4 335,52  HIV infect.adults &childr.over 12 yrs. with progress.immunodefic.  und.plasma conc.curve, plasma conc.of other compds.that are me-
       719297-001: 300 mg, 60, R4 829,49  (S4) TABS, A40/20.2.8/0244  tabol.by CYP3A4 poss. decr., AUC & C max of indinavir/saquinavir &
       Dosage: Ther. should be init.by.physic. exper.in managem.of HIV   707300-001: 60, R189,66  clarithromycin decr., incr.freq.of S/E with ritonavir, rifampicin decr.
       infect. Tropism test/resist.test. & treatm.hist.should guide use.  Dosage: Admin.in combinat.with other ARV’s.  AUC & C max , methadone plasma lev. decr.result.in opiate withdr.signs
       Adults: Recomm.dos: 150 mg, 300 mg or 600 mg 2xdly.depend.   Adults & childr.over 12yrs: 1 tab. 2xdly.  in HIV infect.IV drug users, St John’s Wort reduc.efavirenz plasma
       on interacts. with co-admin.ARV ther.& other meds.  Contraindications: Abnorm.low neutrophil counts /haemoglobin   conc.reduc.eff.& developm.of resist.
       Concom.CYP3A4 inhibits. (with/-out CYP3A4 induc.) incl.  lev., childr.und. 12 yrs.due to insuffic. data & fix.dos.combinat., safety
       protease inhibits. (except tipranavir/ ritonavir)/ delavirdine/   in pregn. not est., breastfeed.not recomm., concom.IV ganciclovir/   CIPLA EFAVIRENZ, Cipla Medpro [P/S]
       ketoconazole / itraconazole/ clarithromycin/ other strong   foscarnet not recomm.  Efavirenz.
       CYP3A4 inhibits (e.g. nefazodone, telithromycin): 150 mg 2xdly.  Side effects: Bld.dyscras., pancreatit., lact. acidos. in absence of   Indications: In combinat.with other antiretrovir. agents for HIV-1
       Other concom.meds. incl tipranavir/ritonavir/ nevirapine/ all   hypoxaem.& sev. hepatomegaly with steatos., headache, malaise,   infect.adults, adolesc.& childr. weigh. 40 kg and above.
       NRTIs & enfuvirtide: 300 mg 2xdly.  GI disturbs., insom., cough, nas.sympts., musculoskelet. pain, pe-  (S4) TABS, 41/20.2.8/0106
       CYP3A4 induc.(without strong CYP3A4 inhibit.) incl. efa-  riph.neuropathy, rash, fev., myalg., paraesth., asthen., CNS effs.,   709331-001: 600 mg, 30, R184,19
       virenz /rifampin/ carbamazepine/ phenobarbital & pheny-  sweat., dyspn., flu-like syndr., chest & gen.pain, urin.freq., chills,   Dosage: Admin.in combinat.with a protease inhibit./ nucleoside
       toin: 600 mg 2xdly.           urticar., prurit.            analog. Admin.on empty stomach. Avoid admin.with a fatty meal
                                                                                   st
       Ren.impairm: Refer to prescrib.lit.for dos.interv. adjustm.& dos.  Special precautions: Opportunist.infects & other HIV complicat.  as absorpt. incr., consid.bedt.dos.dur.1  2-4 wks ther.& in pts.ex-
       recomm.in pts.with ren.impairm. receiv. potent.CYP3A4 inhibits.  still poss., not proven to prev. transmiss., monit.haematolog. para-  per.neurologic.effs.
       Contraindications: Safety in pregn/paed.pts.not est., lactat., hy-  met., in case of sev. anaem./myelosuppress./pre-exist.bone mar-  Adults: Recomm.dos.: 600 mg once dly. Adolesc. & childr.(17
       persens.to soya lecithin/relat.food prod.  row compromise where dos.adjustm.may be reqd./ where discont.  yrs.& und): 600 mg at bedt. Use only in adults & childr.weigh.
       Side effects:  Dizzin., paraesthes., dysgeus., somnol., loss of con-  of one of the act.necess.use separ. preps., discont.use if pancreat.  great. than or equal to 40 kg.
       sciousn., epilep., convuls., fac.palsy, polyneurop., areflex. ,cough,   suspect., suspend. if aminotransferase lev.elev.rapidly/ hepatomeg-  Contraindications: Concom.terfenadine/ astemizole/cisapride/
       resp.distr., bronchosp., naus., vomit., abdom.pain/distens., dys-  aly/metabol.acidos.develop., crosses placenta, monit.phenytoin bld.  midazolam/triazolam/ergot derivat.as ser./life threat.adverse effs.
       peps., constip., pancreatit., rect.haemorrh., rash, prurit., musc.  lev., consid.advers. effs. of other ARV’s, ren./hepat.impairm., elder-  poss., pregn. & lactat., childr.weigh.&lt;40 kg, concom.St John’s Wort.
       spasms, back pain, myosit., asthen., insomn., lab.abnorm.incl.incr.  ly, unclear if adv.effs.are drug relat./part of underly. dis. process.  Side effects: Weight gain/loss, CNS effs., abnorm. co-ordinat.,
       alanine aminotransfer./incr.aspartate aminotransfer./incr. gamma-  Drug interactions: Poss.interacts.with meds. eliminat.by act.ren.  convuls., paraesthes., periph. neuropathy, trem., aggrav.depress.,
       glutamyltransfer., decr.weight, MI, myocardial ischaem., pancy-  secret., trimethoprim incr. lamivudine plasma lev., phenytoin bld.  impot., libido changes, speech disords., abnorm. vis., tinnit., taste
       topen., neutropen., lymphadenopathy, ren.fail., polyur., pneum.,   lev.low., incr. incid.of neutropen.with paracet.& zidovudine, zido-  pervers., palpitat., flush., tachycard., astham, sinusit., dyspn., URTI,
       hepat. cirrhos., hallucinat.  vudine metabol.poss.alt.by meds.direct.inhibit. hepat.microsom.  GI disturbs., malabsorpt., hepatit., hepat.fail., skin reacts.incl.rash/
       Special precautions: Eval.pts.with signs/ sympts. of hepatit/al-  metabol./competit.glucuronidat. inhibit., poss.incr.toxic.risk with   erythema multiforme & Stev. John. syndr., alopec., incr.sweat., acne,
       lerg.react.follow.use immed., prescribe as part of antiretrovir.com-  potent nephrotox. / myelosuppres.meds., in vitro ribavirin/stavu-  nail disords., skin discolourat., arthralg./myalg., myopathy, fatig., al-
       binat.regim., only use when only CCR5-trop. HIV-1 is detectable (i.e.   dine is antagonist., probenecid incr.zidovudine mean half-life &   coh.intol., allerg.reacts., asthen., hot flush., flu-like sympts., malaise,
       CXCR4/dual/mix.trop.vir.not detect.) as determin.by adeq.validat.&   area und.plasma conc.curve.  pain, redistribut./accumulat.of body fat, syncope, rais.ser.cholester.&
       sensitiv.detect.meth., ther.to start shortly aft.tropism test., safety &   triglycerid.conc., incr.tot. cholester.
       effic. not est.in treatm-naïve adult pts., ensure appropr. dos.adjustm.  CIPLA DUOVIR & CIPLA EFAVIRENZ 600, Cipla Medpro [P/S]  Special precautions: Must not be used as monother./ add.on as
       when co-admin.with CYP3A4 inhibits. &/or induc.as conc./therapeut   Cipla Duovir: Lamivudine 150 mg, zidovudine 300 mg.  sole agent to fail.regim., ser.nerv.syst.& psych.sympts.report., use
       effs.poss. affect., risk of transmiss.not reduc., not a cure, caut.in pts.   Cipla Efavirenz: Efavirenz 600 mg  barrier contracept.in combinat.with other methods, consid. alter-
       at incr.risk for CV events/hist.of postur. hypotens./ concom.meds.  Tablets co-packaged  nat.to clarithromycin, teratogenic. report., pregn. test in women of
       known to low.BP, immune reconstit.syndr.where pts.with sev.immun.   Indications: HIV infect.adults/adolesc.& childr. 40 kg & above.  childbear.potent. bef.init.ther., pass.into breast milk, ref.to prod.lit.
       defic. may develop inflamm.react.to asymptomat./ resid.opportunist.  (S4) TABS, 41/20.2.8/0218  when prescrib.other meds., consid.simultan. discont. of all antiret-
       pathog.necessit.furth.eval. & treatm., incr.freq.of liv.funct.abnorm.  712993-001: 90(Duovir: 60, Efavirenz: 30), R599,48  rovir.meds.if combinat. regim. is interrupt.because of suspect.intol.&
       dur.combinat. antiretrov.ther.in pts.with pre-exist.liv.dysfunct.& pts.  Dosage: Adults & childr.over 12 yrs: 1 Cipla Duovir tab.2xdly. &   restart medicat.at same time upon resolut.of intol. sympts., intermitt.
       should be monit.accord.to.stand.pract., consid. discont.in pts.with   1 Cipla Efavirenz tab.once dly. pref.at bedt.  monother./sequent. reintroduct. not advis., discont.in sev.rash & con-
       signs/sympts.of ac.hepatit., caut.when treat.pts with reduc.hepat.  Contraindications: Abnorm.low neutrophil counts /haemoglobin   sid.prophylax.with appropr.anthistam./ corticoster. for mild to mod.
       funct./ pts.with hepatit.B/C co-infect./pts.&gt;65 yrs.since exper. limit.,   lev., childr.und. 12 yrs.due to insuffic.data & fix.dos.combinat., con-  rash to improv.tol.& resolv.rash, be alert to psychos.-like reacts.&
       caut.& dos.adjustm.advis.in pts.with ren.impairm. (CL cr &lt; 80 ml/min)   com.ribavirin & stavudine, childr.weigh.&lt;40 kg, concom. terfenadine/   sev. ac.depress.reports, ment. illn./subst.abuse hist., suicid.ideat./
       who are also tak. potent. CYP3A4 inhibits., avoid potent.hazard.   astemizole/cisapride/midazolam/ triazolam/ ergot derivat.as ser./life   attempts.report., liv.impairm., monit.liv.enzymes partic.in known/sus-
       tasks as dizzin.poss., no breastfeed as potent.for HIV transmiss.&   threat.adverse effs.poss., pregn.& lactat., concom.IV ganciclovir/   pect. hepatit.B/C infect.hist./ concom.hepatotox. meds., cholestrol.
       poss.undesir.effs.in inft.    foscarnet not recomm., concom.St John’s Wort.  monit., use not assess.in paed. pts.bel.3 yrs./weigh.&lt;13 kg.
       Drug interactions:  Co-admin.with CYP3A4 induc.may decr.  Side effects: Bld.dyscras., pancreatit., lact. acidos. in absence of   Drug interactions: Plasma conc.of other compds. that are me-
       conc.& reduc.therapeut.effs., co-admin. with CYP3A4 ihibits.may   hypoxaem.& sev. hepatomegaly with steatos., headache, insom.,   tabol.by CYP3A4 poss.decr., AUC & C max of indinavir/saquinavir &
       incr.conc., refer to prescrib.lit.for interact.& dos.recomm.with com-  periph. neuropathy, cough, nas.sympts., GI disturbs., pancreatit.,   clarithromycin decr., incr.freq.of S/E with ritonavir, rifampicin decr.
       mon. prescrib.meds.           trans.rise in liv.enzym., musculoskelet. pain, fatig., malaise, loss of   AUC & C max ,, methadone plasma lev.decr.result.in opiate withdr.signs
                                                                  in HIV infect.IV drug users, expect.reduc.conc.with St John’s Wort.
       CIPLA ABACAVIR, Cipla Medpro [P/S]  ment. acuity, somnol., dizzin., anx., depress., taste pervers., dyspn.,
                                     rash, sweat., urticar., prurit., myalg., urin.freq., fev., asthen., flu-like
       Abacavir                      syndr., chest & gen.pain, chills, myopathy, skin/nail & oral mucosa   CIPLA LAMIVUDINE, Cipla Medpro [P/S]
       Indications: Antiretroviral combinat.ther.for HIV treatm.in infect.  pigmentat., convuls., weight gain/loss, abnorm.dreams, hypoaes-  Lamivudine
       adults & childr.              thes., CNS effs., abnorm. co-ordinat., atax., aggrav.depress., im-  Indications: In combinat.with other ARV agents for HIV infect adults
       (S4) TABS, 41/20.2.8/0692     pot., libido changes, speech disords., abnorm.vis., tinnit., palpitat.,   with progress.immunodefic. who have no prior antiretroviral ther./or
       714098-001: 300 mg, 60, R1 130,56  flush., tachycard., asthma, sinusit., URTI, gastro-oesphag.reflux,   who have prev. been treat.with zidovudine.
       (S4) ORAL SOL., 41/20.2.8/0857  malabsorpt., hepatit., hepat. fail., alopec., acne, eczema, erythema   (S4) TABS, 35/20.2.8/0248, 41/20.2.8/0140
       714099-001: 20 mg/ml, 240 ml, R426,66  multiforme & Stev.John.syndr., alcoh.intol., allerg. reacts., hot flush.,   701282-003: 150 mg, 60, R100,75
       Dosage: For use by physic.exper.in HIV managem.  redistribut./accumulat.of body fat, rais.ser.cholester.& triglycerid.  709337-001: 300 mg, 30, R100,75
       Adults & adolesc.over 12 yrs: Recomm.dos: 300 mg/15 ml oral   conc., incr.tot. cholester.  Dosage: In combinat.with other ARV’s
       sol.2xdly. Childr.3 mnths-12 yrs: Recomm.dos: 8 mg/kg 2xdly up   Special precautions: Opportunist.infects & other HIV compli-  Adults & adolesc.old.than 12 yrs: 150 mg 2xdly OR 300 mg once
       to max.600 mg dly.            cat.still poss., not proven to prev. transmiss., monit.haematolog.  dly. Low bm (&lt;50 kg): Recomm. dos: 2 mg/kg 2xdly.
       Contraindications: Hepat.impairm., pregn.& breast feed., childr.  paramet., in case of sev. anaem./myelosuppress./pre-exist.bone   Contraindications: Safety in pregn.& lactat.not est.
       und.3 mnths. Sol.also: Heredit. fruct. intol.  marrow compromise where dos.adjustm.may be reqd. /where   Side effects: Lact.acidos.& sev.hepatomegaly with fatalat., bld.
       Side effects: Fatal hypersens.reacts.indicat.of multi-organ/body   dyscras., periph.neuropathy, paraesthes., depress.disords., dizzin.,
       syst.involvem.with the follow. sympts: abdom.pain, mouth ulc.,   discont.of one of the act.necess.use separ.preps., discont.use if   headache, insomn., other sleep disords., ear discharge/ erythema/
                                     pancreat.suspect., suspend.if aminotransferase lev.elev.rapidly/
       dyspn., sore throat, cough, fev., fatig., malaise, oed., lymphad-  pain/swell., arthralg., musc.disords. incl.rhabdomyolys., fatig., ma-
       enopathy, hypotens., conjunctivit., anaphylax., headache, par-  hepatomegaly/metabol.acidos.develop., crosses placenta, efa-  laise, fev., ENT infects., nas.sympts., cough, skin rash, alopec., GI
                                     virenz must not be used as monother. / add.on as sole agent to
       aesthes., lymphopen., hepat.fail., myalg., myolys., arthralg., elev.  fail.regim., ser.nerv.syst. & psych.sympts.report.with efavirenz,   disturbs., pancreatit., splenomegaly, lymphadenopathy, body fat
       creatine phosphokin., ren.fail., resp.dis., flu-like illn., gastroenterit.,   consid. alternat. to clarithromycin, use barrier contracept. in ad-  redistribut., hyperglycaem., post-treatm.exacerbat.of hepatit.B, hy-
       hepatotox.consist.lact.acidos./ sev.hepatomegaly with steatos.  dit.to OC’s as potent.interacts.not stud., teratogenic.report.with   persens.reacts.incl.anaphylax.
       partic.in women, N&V, diarrh., fev., fatig., headache, paraesthes.,   efavirenz, pregn.test in women of childbear.potent.bef.init.ther.,   Special precautions: Developm.of opportunist. infects.& other
       hypersens. sympts worsen.with cont.ther., hypersens. reacts.are   pass.into breast milk, ref.to prod.lit.when prescrib other meds.,   HIV complicat.may cont., ther.not proven to prev.transmiss., lami-
       more sev.on re-challeng.incl. life-threaten.hypotens.& death pres.  vud./zidovud. combinat. in ren.impairm., concom.zalcitabine not
       within hrs., anorex., elev.bld.gluc.& triglyceride conc., insomn.,   non combin.preps.allow.for dos.adjustm. recom.in ren./hepat.im-  recomm., ref.to zidovud.P/I if admin.concom., ren./ hepat.impairm.,
                                     pairm., elderly, unclear if adv. effs.are drug relat./other concom.
       pancreatit., skin rash (usual.maculopapul./urticar.) without sys-  advanc. cirrhot.liv.dis., discont. use if pancreat. suspect., confirm
       tem. sympts., erythema multiforme, Stev..-Johns.syndr., tox.epi-  HIV meds./ part of underly.dis.process., consid.simultan. discont.   lact.acidos.by demonstrat. metabol.acidos., discont.ther.if clinic.
                                     of all antiretrovir.meds.if combinat.regim. is interrupt.because of
       derm.necrolysis, lethargy.                                 find.suggest.of hepatotox./lact.acidos., consid. adv. effs.from other
       Special precautions: Hypersens.reacts.charact. by multi-organ/  suspect.intol.& restart medicat.at same time upon resolut.of in-  ARV’s, unclear whether adv.effs. are drug-relat./underly.dis.process.
                                     tol. sympts., discont.in sev.rash & consid.prophylax. with appropr.
       body syst.involvem.have proven fatal, perman.discont.ther.if hy-  Drug interactions: Trimethoprim incr.plasma conc., intracell.phos-
       persens.react. cannot be excl.with certainity, opportunist.infects.   anthistam./corticoster.for mild to mod. rash to improv.tol.& resolv.  phorylat.of zalcitabine inhibit., ren.excret.poss.inhibit.by meds.elimi-
                                     rash, intermitt. monother./sequent.reintroduct.not advis., be alert
       & other HIV complicat.may still devel., advis.pt. that antiretrovir.  nat.by act. ren. secret.
       ther.will not prev.transmiss.& appropr.precaut.to contin., pts.to be   to psychos.-like reacts.& sev.ac.depress.reports, ment. illn./subst.  CIPLA NEVIRAPINE, Cipla Medpro [P/S]
       made aware of dangers of hypersens.& to contact dr.immed., do   abuse hist., suicid.ideat./ attempts. report., monit.liv.enzymes par-
       not re-challeng.pts.who develop hypersens. reacts., risk fact.for liv.  tic.in known / suspect. hepatit.B/C infect.hist./concom. hepatotox.   Nevirapine.
                                                                  Indications: In combinat.with other antiretrov. agents for HIV-
       dis., potent.clinic. benef. outweighs carcinogen.risk, mild myocard.   meds., cholestrol.monit., use not assess. in paed. pts.bel.3 yrs./
       degenerat.aft.2 yrs. observ.in rats.  weigh.&lt;13 kg, discour. concom.self-medicat.  1 infect.
       Oral Sol: Cont.sorbit.poss giv.rise to abdom.pain.  Drug interactions: Poss.interacts.with meds. eliminat.by act.ren.  (S4) TABS. 36/20.2.8/0423.
       Drug interactions: Syst.methadone clear.incr., poss. interact.with   secret., trimethoprim incr. lamivudine plasma lev., phenytoin bld.  704036-001: 200 mg, 60, R299,32  st
       retinoid cmpds.but not stud.  lev.low., incr. incid.of neutropen.with paracet.& zidovudine, zido-  Dosage: Adhere strict.to dos.dur.14 day lead-in period. Dur.1  2
                                     vudine metabol.poss.alt.by meds.direct.inhibit. hepat.microsom.  wks ther.it’s critic.to monit.for sev.& life-threat.skin reacts.& ser.
       CIPLA DUOVIR, Cipla [P/S]     metabol./competit.glucuronidat. inhibit., poss.incr.toxic.risk with   hepatit./ hepat. fail. Consult.prod.info.of each therapeut. compon.
       Lamivudine 150 mg, zidovudine 300 mg.  potent nephrotox. / myelosuppres.meds., in vitro ribavirin/stavu-  of regim.bef.init.treatm. Do not alter.dos. If dos. skip. do not double</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page301.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>&nbsp;&nbsp;&nbsp;<a href="page303.html">303</a>&nbsp;&nbsp;&nbsp;<a href="page304.html">304</a>&nbsp;&nbsp;&nbsp;<a href="page305.html">305</a>&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>
             </td>
             <td width="35%"><a href="page303.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page303.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
